← All Posts
CTM
CytomX Therapeutics, Inc.
June 18, 2026
•
Author: Phil Ratcliff
•
CTMX
| Item |
Proposal |
Vote |
| 1 |
To elect two directors with terms to expire at the 2029 Annual Meeting of Stockholders. |
|
| 1a |
Matthew P. Young |
✓ For(18.123)
|
| 1b |
Elaine V. Jones, Ph.D. |
✓ For(18.123)
|
| 2 |
To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. |
✓ For(18.123)
|
| 3 |
To approve an amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 shares to 600,000,000 shares. |
✓ For(18.123)
|
| 4 |
To approve an amendment to our Amended and Restated 2015 Equity Incentive Plan. |
✓ For(18.123)
|
| 5 |
To approve an amendment to our Amended and Restated Employee Stock Purchase Plan. |
✓ For(18.123)
|
| 6 |
To approve, on a nonbinding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders. |
✓ For(18.123)
|
| 7 |
To hold a non-binding advisory vote on the frequency of future advisory votes by stockholders on the compensation of our named executive officers. |
1 Year
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial